1. Generics Bulletin
  2. >>Products

Henlius Kicks Off Denosumab Trial

Chinese Firm Doses First Patient In Phase I Trial For Xgeva/Prolia Biosimilar

 
• By Dave Wallace

Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.

Clinical Trial
Shanghai Henlius has begun dosing in Phase I trials for denosumab • Source: Shutterstock

Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar rival to Amgen’s Xgeva/Prolia (denosumab).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products